Open menu

Nanotechnology General News

The latest news from academia, regulators
research labs and other things of interest

Posted: November 2, 2007

Applied Nanoscience Formulation Tests Successfully Against MRSA

(Nanowerk News) Applied Nanoscience Inc. (ANI) (PINKSHEETS: APNN) today announced that it has achieved highly successful test results for its proprietary silver nanoparticle formulation against methicillin resistant Staphylococcus aureus, or MRSA. The challenge produced a >99.99% reduction (4+log) in two minutes when coated on filter media and directly introducing the challenge organism. Testing was conducted at an independent, nationally recognized BSL-3 laboratory.
According to U.S. government researchers, MRSA, also known as the Superbug by the media, affects more 90,000 Americans annually. MRSA doesn't respond to penicillin-related antibiotics, which were previously used to treat them. The bacteria can be carried by healthy people, and can reside on their skin or in their nasal passages. While most MRSA cases are mild, they can turn into deadly flesh-destroying infections if they enter the bloodstream.
Separately, ANI and Emergency Filtration Products, Inc. (EFP) announced that they have completed another successful round of testing against the avian influenza strain H9N2. The test, which was designed to assess the efficacy of ANI's nanoparticle formulation when applied on filter media in a production environment, completely inactivated the strain in two minutes. Testing was conducted at a well-known independent BSL-3 laboratory.
ANI is working with EFP to conduct all testing necessary to support EFP's new 510k submission to the FDA for EFP's NanoMask. ANI will assist EFP to conduct the final phase of testing necessary prior to EFP's new submission to the FDA. EFP has a license to use ANI's proprietary silver nanoparticle formulation for personal protection masks and military uses.
Safe Harbor Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. ANI does not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the companies could differ significantly from such forward-looking statements.
Source: Applied Nanoscience Inc.